Galectins and Ovarian Cancer

Shimada, Chisa; Rui, Xu; Al-Alem, Linah; Stasenko, Marina; Spriggs, David R.; Rueda, Bo R.

doi:10.3390/cancers12061421

Cited by 21 publications

(30 citation statements)

References 168 publications

(267 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, the literature seems to suggest that galectin overexpression is a poor prognostic factor that enhances the development, progression, and metastasis of several cancer types 8 . In addition, monitoring galectin‐mediated pathways could be of great importance in improving the quality of care 28 …”

Section: Discussionmentioning

confidence: 99%

Galectins‐1, ‐3, ‐7, ‐8 and ‐9 as prognostic markers for survival in epithelial ovarian cancer: A systematic review and meta‐analysis

Pergialiotis

Papoutsi

Androutsou

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Background Galectins are a family of proteins that have recently emerged as regulators of cancer biology. Objectives To investigate the impact of peritumoral and tumoral galectin expression on ovarian cancer prognosis. Search strategy We searched Medline, Cochrane, and EMBASE databases from inception until March 22, 2020. Selection criteria All studies correlating galectins and ovarian cancer prognosis were selected. Data collection and analysis The literature search presented 11 studies, which contained 1034 patients. Meta‐analysis was performed with RevMan 5.3 software. Main results Studies were stratified into two groups depending on the location of galectin expression (peritumoral stroma or nucleus/cytoplasm of tumor cells). Tumoral galectin‐7 and galectin‐9 expression was significantly associated with poor overall survival (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.32–3.21, P = 0.001; OR 1.71, 95% CI 1.27–2.30, P < 0.001, respectively). The total effect of high tumoral expression of galectins in overall survival and progression‐free survival was significant (OR 1.51, 95% CI 1.02–2.23, P = 0.04; OR 2.76, 95% CI 1.73–4.40, P < 0.001, respectively). Conclusions Our results suggest that galectins are implicated in ovarian cancer prognosis; however, further research is needed to ascertain their actual importance as well as their diagnostic accuracy.

show abstract

Section: Discussionmentioning

confidence: 99%

Galectins‐1, ‐3, ‐7, ‐8 and ‐9 as prognostic markers for survival in epithelial ovarian cancer: A systematic review and meta‐analysis

Pergialiotis

Papoutsi

Androutsou

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Data on the interaction of galectin-9 and TIM-3 are contradictory. Galectin-9 is involved in oncogenesis, cell transformation, cell cycle regulation, cell adhesion, and angiogenesis [ 13 ]. It was shown that galectin-9 binding to the TIM-3 molecule on the surface of T-helpers terminates the T-cell antitumor immune response [ 14 ].…”

Section: Immune Checkpoint Receptorsmentioning

confidence: 99%

The Features of Checkpoint Receptor—Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition

et al. 2022

View full text Add to dashboard Cite

To date, certain problems have been identified in cancer immunotherapy using the inhibition of immune checkpoints (ICs). Despite the excellent effect of cancer therapy in some cases when blocking the PD-L1 (programmed death-ligand 1) ligand and the immune cell receptors PD-1 (programmed cell death protein 1) and CTLA4 (cytotoxic T-lymphocyte-associated protein 4) with antibodies, the proportion of patients responding to such therapy is still far from desirable. This situation has stimulated the exploration of additional receptors and ligands as targets for immunotherapy. In our article, based on the analysis of the available data, the TIM-3 (T-cell immunoglobulin and mucin domain-3), LAG-3 (lymphocyte-activation gene 3), TIGIT (T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains), VISTA (V-domain Ig suppressor of T-cell activation), and BTLA (B- and T-lymphocyte attenuator) receptors and their ligands are comprehensively considered. Data on the relationship between receptor expression and the clinical characteristics of tumors are presented and are analyzed together with the results of preclinical and clinical studies on the therapeutic efficacy of their blocking. Such a comprehensive analysis makes it possible to assess the prospects of receptors of this series as targets for anticancer therapy. The expression of the LAG-3 receptor shows the most unambiguous relationship with the clinical characteristics of cancer. Its inhibition is the most effective of the analyzed series in terms of the antitumor response. The expression of TIGIT and BTLA correlates well with clinical characteristics and demonstrates antitumor efficacy in preclinical and clinical studies, which indicates their high promise as targets for anticancer therapy. At the same time, the relationship of VISTA and TIM-3 expression with the clinical characteristics of the tumor is contradictory, and the results on the antitumor effectiveness of their inhibition are inconsistent.

show abstract

“…Hanahan and Weinberg defined hallmarks of most cancers which describe the biological capabilities essential for carcinogenesis [ 31 ]. There are a number of papers published regarding the subject of cancer (development) and the roles of (targeting) galectins, and even galectin-7 in particular [ 13 , 30 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. Nevertheless, our goal for this section is to provide the reader with a brief overview of the presence and roles of galectin-7 in most cancers/cancer types by covering mostly recent publications.…”

Section: Galectin-7 a Convergence Of Pathology With Physiologymentioning

confidence: 99%

Functions and Inhibition of Galectin-7, an Emerging Target in Cellular Pathophysiology

2021

View full text Add to dashboard Cite

Galectin-7 is a soluble unglycosylated lectin that is able to bind specifically to β-galactosides. It has been described to be involved in apoptosis, proliferation and differentiation, but also in cell adhesion and migration. Several disorders and diseases are discussed by covering the aforementioned biological processes. Structural features of galectin-7 are discussed as well as targeting the protein intracellularly or extracellularly. The exact molecular mechanisms that lie behind many biological processes involving galectin-7 are not known. It is therefore useful to come up with chemical probes or tools in order to obtain knowledge of the physiological processes. The objective of this review is to summarize the roles and functions of galectin-7 in the human body, providing reasons why it is necessary to design inhibitors for galectin-7, to give the reader structural insights and describe its current inhibitors.

show abstract

Galectins and Ovarian Cancer

Cited by 21 publications

References 168 publications

Galectins‐1, ‐3, ‐7, ‐8 and ‐9 as prognostic markers for survival in epithelial ovarian cancer: A systematic review and meta‐analysis

Galectins‐1, ‐3, ‐7, ‐8 and ‐9 as prognostic markers for survival in epithelial ovarian cancer: A systematic review and meta‐analysis

The Features of Checkpoint Receptor—Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition

Functions and Inhibition of Galectin-7, an Emerging Target in Cellular Pathophysiology

Contact Info

Product

Resources

About